Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: a real-world study of 108 patients
The ICI and radiotherapy combination was effective and well-tolerated in real-world patients, achieving more favorable results compared with historical ones and providing a new multimodality therapy for patients with recurrent and metastatic HCC.
Authors
- Yueping Liu (ORCID: https://orcid.org/0000-0002-6152-4807)
- Jing Hao (ORCID: https://orcid.org/0000-0002-8512-1826)
- Hui Fang (ORCID: https://orcid.org/0000-0002-8982-5978)
- Jianguo Zhou
- Yongkun Sun (ORCID: https://orcid.org/0000-0003-3302-6023)
- B. Chen (ORCID: https://orcid.org/0000-0001-9158-8433)
- Yefan Zhang
- Ye‐Xiong Li (ORCID: https://orcid.org/0000-0003-0985-235X)
- Huiying Zeng
- Pan Zhao (ORCID: https://orcid.org/0000-0001-7579-9783)
- Shulian Wang (ORCID: https://orcid.org/0000-0001-7322-9621)
- Liming Wang (ORCID: https://orcid.org/0000-0003-1382-9195)
- Wenwen Zhang (ORCID: https://orcid.org/0000-0003-2443-3559)
- Feng Ye
- Fan Wu (ORCID: https://orcid.org/0000-0003-1025-2298)
- Yan Song (ORCID: https://orcid.org/0000-0001-5833-9654)
- Yirui Zhai
- Wei Sun (ORCID: https://orcid.org/0000-0001-7511-529X)
- Ningning Lu
- Shunan Qi
- Lingxia Xin
- Yong-Wen Song
- Yuan Tang (ORCID: https://orcid.org/0000-0003-1888-8012)
- Wen Zhang (ORCID: https://orcid.org/0000-0003-2193-6222)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-04
- DOI
- https://doi.org/10.3389/fimmu.2025.1594577
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00